Form 4: Outlook Therapeutics Director Andong Huang Acquires Stock Options

Director Andong Huang acquired stock options in Outlook Therapeutics, Inc. through grants under the company's equity incentive plan and non-employee director compensation policy.

Summary

• Andong Huang, a director of Outlook Therapeutics, Inc., acquired stock options on October 1, 2024, and October 3, 2024.
• These options were granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan.
• On October 1, 2024, Huang acquired 56,636 stock options with an exercise price of $5.22, vesting fully on October 1, 2025.
• On the same date, Huang acquired an additional 23,509 stock options with an exercise price of $5.22, also vesting fully on October 1, 2025.
• On October 3, 2024, Huang acquired 10,984 stock options with an exercise price of $5.25, vesting in four equal quarterly installments and fully vesting on September 30, 2025.
• The options are subject to acceleration upon a Change in Control, provided continuous service is maintained.
• Lawrence Kenyon, Attorney-in-Fact, signed the report on October 3, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices, indicating confidence in the company's future.

Positives

• The option grants align the director's interests with the company's long-term performance.
• The vesting schedules incentivize continued service to the Issuer.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize directors and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard component of compensation packages in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedules and change in control provisions are typical features designed to retain directors and align their interests with long-term shareholder value.
• Comparable companies such as Alimera Sciences, Ocular Therapeutix, and Kala Pharmaceuticals also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grants could have a minor dilutive effect on existing shareholders.
• The grants incentivize the director to contribute to the company's success, potentially benefiting all stakeholders.

Key Dates